Nachrichten zur ChemoCentryx Inc. Aktie

ChemoCentryx to Host Virtual R&D Day on April 14, 2021

MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will…

Strength Seen in ChemoCentryx (CCXI): Can Its 8.6% Jump Turn into More Strength?

ChemoCentryx (CCXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…

Insiderhandel: Aufsichtsrat verkauft Aktien von ChemoCentryx im Wert von 114.980$

Parker, Geoffrey M. - Aufsichtsrat - Tag der Transaktion: 2021-03-04...…

Insiderhandel: Aufsichtsrat verkauft Aktien von ChemoCentryx im Wert von 1.691.468$

Parker, Geoffrey M. - Aufsichtsrat - Tag der Transaktion: 2021-03-05...…

ChemoCentryx, Inc.: 8-K Report

8-K...…

ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors

MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of…

ChemoCentryx, Inc. 2020 Q4 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx, Inc.: 8-K Report

8-K...…

ChemoCentryx Inc (CCXI) Q4 2020 Earnings Call Transcript

CCXI earnings call for the period ending December 31, 2020....…

ChemoCentryx (CCXI) Reports Q4 Loss, Misses Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -34.38% and -51.14%, respectively, for the quarter ended December 2020. Do the…

ChemoCentryx, Inc.: 10-K Report

10-K...…

ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis --…

ChemoCentryx names new EVP & COO

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx announces peer reviewed publication of Phase 3 Avacopan data

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in…

Insiderhandel: Principal Acctg Officer verkauft Aktien von ChemoCentryx im Wert von 271.960 $

Kwan, Pui San - Vorstand - Tag der Transaktion: 2021-01-25...…

ChemoCentryx (CCXI) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx to Participate in Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.…

ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data

ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the…

Pharmabranche - Vifor-Joint-Venture präsentiert erste Ergebnisse zu Nierenmedikament

Das Gemeinschaftsunternehmen Vifor Fresenius Medical Care Renal Pharma (VFMCRP) und sein Partner ChemoCentryx haben am Montag die ersten Ergebnisse der…

ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

MOUNTAIN VIEW, Calif. and ST. GALLEN, Switzerland, Dec. 21, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius…

Why Is ChemoCentryx (CCXI) Up 2% Since Last Earnings Report?

ChemoCentryx (CCXI) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.…

ChemoCentryx (CCXI) Reports Wider-Than-Expected Q3 Loss

ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020....…

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx Inc (CCXI) Q3 2020 Earnings Call Transcript

CCXI earnings call for the period ending September 30, 2020....…

ChemoCentryx (CCXI) Reports Q3 Loss, Lags Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -25.00% and -60.46%, respectively, for the quarter ended September 2020. Do the…

Recap: ChemoCentryx Q3 Earnings

Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down…

ChemoCentryx, Inc.: 10-Q Report

10-Q...…

ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis

-- Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal…

ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan

ST. GALLEN, Switzerland and MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal…

Pharma - Vifor Fresenius macht mit Medikament weiteren Schritt bei EU-Zulassung

Das Gemeinschaftsunternehmen Vifor Fresenius Medical Care Renal Pharma (VFMCRP) kommt zusammen mit seinem Partner ChemoCentryx bei den Zulassungsplänen für Avacopan…

ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020

MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Companys…

ChemoCentryx downgraded to neutral from overweight at J.P. Morgan

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)

-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III…

ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment

-- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Companys orally administered small molecule…

ChemoCentryx prices equity offering at $58

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…